Showing 101-110 of 10216 results for "".
GEP Testing in Surgical Oncology
https://practicaldermatology.com/series/updates-in-skin-cancer/gep-testing-in-surgical-oncology/35601/Surgical oncologist J. Michael Guenther, MD, discusses how to use gene expression profile (GEP) testing for managing melanoma patients.Significant FDA Approval for PDT
https://practicaldermatology.com/series/pdt-in-practice/significant-fda-approval-pdt/29102/Dr. Jonathan S. Weiss discusses the importance of a recent FDA approval involving dosing of a PDT photosensitizer for both lesion-directed and field-directed treatment of actinic keratosis.Managing Patients with Atypical Nevi and Melanoma
https://practicaldermatology.com/topics/skin-cancer-photoprotection/managing-patients-with-atypical-nevi-and-melanoma/19982/Monitoring patients with several atypical nevi who are at high risk for melanoma is very challenging. Steven Q. Wang, MD offers tips for improving diagnostic accuracy and discusses the role of dermoscopy in detecting melanoma as well as non-melanoma skin cancers at much earlier rates.James Del Rosso, DO: Thoughts on the FDA Citizen's Petition for Acne Products with Benzoyl Peroxide (BPO)
https://practicaldermatology.com/topics/acne-rosacea/james-del-rosso-do-thoughts-fda-citizens-petition-acne-products-benzoyl-peroxide-bpo/24173/James Q. Del Rosso, DO, a dermatologist and president of The American Acne and Rosacea Society (AARS), weighs in on a recent report from Valisure which finds that benzene can form at elevated levels in products for acne that contain benzoyl peroxide (BPO). The interview was conducted by Neal Bhatia,Thoughts on HIPAA
https://practicaldermatology.com/topics/practice-management/thoughts-on-hipaa/19206/Michael Sacopulos, JD discusses HIPAA compliance for aesthetic practices. (Recorded June 2013)The State of Private Equity in 2024: Impact on the Practice of Dermatology
https://practicaldermatology.com/columns/practice-management/state-private-equity-2024-impact-practice-dermatology/27173/Physician Growth Partners recently published a white paper, “State of Dermatology Private Equity,” that evaluated market trends, strategies, and more. Practical Dermatology® spoke exclusively with CEO Michael Kroin about how the evolution of private equity is impacting the everyday practitioner andScientifically Speaking: Expert Filler Tips and Cases
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-expert-filler-tips-and-cases/20005/Optimal outcomes with aesthetic injectables depend on choosing the right filler and applying the proper technique. Michael Somenek, MD; Kay Durairaj, MD; Shino Bay Aguilera, DO; and Corey Hartman, MD share cases and discuss the secrets to natural-looking, impressive improvements in the lips, chin,Radiesse for Hands, Alevicyn Cleared
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-radiesse-for-hands-alevicyn-cleared/18898/Merz gets FDA approval for Radiesse for hand augmentation and releases data comparing Xeomin to Botox. Heidi Waldorf, MD, FAAD and Michael Gold, MD, FAAD, comment. Also in this edition, Galderma participate in a White House forum on antibiotic stewardship, and the FDA gives 510(k) clearance to AleviPipeline Watch: Sizing Up a Promising Phase III IL-17 Biologic
https://practicaldermatology.com/topics/psoriasis/pipeline-watch-sizing-up-a-promising-phase-iii-il-17-biologic/21214/Pipeline Watch is a new Q&A feature appearing periodically in Practical Dermatology® that explores the potential of therapeutic agents currently under investigation. In each edition, we will speak with investigators from manufacturing companies to gain insights about the development and investigPros and Cons of DTC Advertising
https://practicaldermatology.com/topics/practice-management/pros-and-cons-of-dtc-advertising/18569/Hilary Baldwin, MD and James Q. Del Rosso, DO sit down with Derm Insider Host Neal Bhatia, MD to weigh the pros and cons of direct-to-consumer advertising on patients. They agree that if done well and with a primary focus on disease state rather than a specific drug, these ads can encourage patients